Study Published in Oncotarget Sheds Light on the Risks of E-cigs

Oncotarget is fast-rising peer-reviewed medical information repository focused on oncology research. The portal recently published first-of-its’-kind study findings that left everyone aghast and shocked. The experiment proved that e-cigarettes had the same adverse effects on the gums on the user as conventional cigarettes end up doing. The groundbreaking project was headed by among others, the lead Environmental Medicine Professor, Irhan Rahman. The investigative team aimed to prove their hypothesis that e-cigarettes did, in fact, cause cellular and molecular damages on the oral cavity of the vapor inhaler.

Vapor Triggers Response

The study was inspired, largely, by the prevailing mindset associated with the use of the now very popular e-cigs. The manufacturers have put up bold advertisements encouraging active smokers to take up their products. By making that change, the conventional cigarette smokers would be saving the healthiest life choice. The scientists observed how the vapor burned and charred the oral cells. The excess heat, in turn, triggers an inflammatory response in an attempt to heal the damaged oral cells. In the end, the person starts manifesting a wide variety of oral complications. The more exposed these cells are to the vapor, the more intense the dental cavity destruction. Additionally, and to further verify the research, previous studies have already demonstrated without a doubt that nicotine, present in the e-cigs vapor, is a known causative factor of gum disease. Follow Oncotarget on Twitter.

Importance of the Study

The lead scientist heading up the study, Professor, Irhan Rahman, however, called for further experiments to build up a better understanding of what really goes on when one smokes an e-cig. These added investigations would pave the way forward for the manufacturers to develop tested products. Other notable institutions and scientists who made this project a sure success were the Department of General Dentistry, UR Department of Environmental Science, Department of Periodontology, Fawad Javed, Georgios E. Romanos and the School of Dental Medicine at the Stony Brook University.

About Oncortarget

Oncotarget is a peer-reviewed website where academics can post their researches and find new study findings as well. It was created by two renowned oncology scientists, Andrei V. Gudkov and Mikhail V. Blagosklonny in 2010. Ideally, the organization intended to limit their scope to only oncology journals but, the unprecedented demand over the years has seen them expand to encompass other categories, for instance, neuroscience and cardiology. Visit his profile on Google Scholar.

Mikhail Blagosklonny And His Work With Rapamycin

Mikhail Blagosklonny is scientist who works as a Professor of Oncology at the Roswell Park Cancer Institute in New York. Being from Russia, he obtained both his M.D. and Ph.D. from the First Pavlov State Medical University of St. Petersburg. He has since emigrated to the United States and contributes to cancer research and discovering effective cancer drugs.

After emigrating to America, he became an Associate Professor of Medicine at the New York Medical College. He was able to use that experience to move onto his next work experience at Ordway Research Institute as a Senior Scientist. He began working at Roswell Park Cancer Institute in 2009.

According to Impact Journals, Mikhail Blagosklonny is an advocate for the cancer drug Rapamycin, and has created a hypothesis about the role of TOR signalling in both aging and cancer.  In his research he noted that the same qualities that made Rapamycin effective at slowing tumor growth could also be effective at slowing the aging process.

Nature.com reported that Mikhail Blagosklonny is so convinced of the effectiveness of Rapamycin on the aging process that he has tried taking it himself. He has also noted that the drug has been approved for more than 15 years with no serious problems reported. He has said that there are fewer side effects with Rapamycin than there are with aspirin.

Mikhail Blagosklonny is also an Editor-In-Chief for three magazines. These magazines are Oncotarget, Aging, and Cell Cycle. He has also himself published over 270 papers in peer-reviewed journals. He has also published reviews and book chapter.

On the aging process, he has written that in his research he has come to a theory that aging is due to the body’s inability to turn off the genetics that lead to growth and development that occurs early in life.